title: Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed?
authors.affiliation: Division of Nephrology and Hypertension, Department of Medicine, Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine, Evanston, Illinois 60201, USA.
authors.forename: Anca
authors.initials: A
authors.lastname: Gal-Moscovici
authors.forename: Stuart M
authors.initials: SM
authors.lastname: Sprague
authors.forename: Alastair J
authors.initials: AJ
authors.lastname: Hutchison
authors.forename: Nirav
authors.initials: N
authors.lastname: Shah
authors.forename: Beth
authors.initials: B
authors.lastname: Piraino
authors.forename: John
authors.initials: J
authors.lastname: Cunningham
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D002136:Calcium, Dietary / Q000008:administration & dosage; D002908:Chronic Disease; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D007674:Kidney Diseases / Q000150:complications*; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D017410:Practice Guidelines as Topic; D018167:Receptors, Calcitriol / Q000819:agonists
chemical_list: D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D010281:Parathyroid Hormone; D010710:Phosphates; D018167:Receptors, Calcitriol; D002118:Calcium